Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Caribou Biosciences Inc.

www.cariboubio.com

Latest From Caribou Biosciences Inc.

If PTAB Backs Berkeley IP Holders' New Patent Claims, CRISPR Licensing Could Be Simplified

The USPTO's PTAB will determine whether UC-Berkeley or Broad Institute holders of CRISPR patents first invented its use in eukaryotic cells. The outcome could either benefit the Berkeley group, which could simplify licensing deals, or maintain the status quo.

Intellectual Property Business Strategies

ERS Genomics Completes 45 CRISPR Licensing Deals To Date, Largely For Screening, Discovery

Despite being ineligible to license its CRISPR technology for human gene and cell therapy applications, ERS is doing considerable business with biopharmas for internal R&D projects.

Deals Intellectual Property

Appointments: C4 Therapeutics, ORIC Pharma, CytRx, Audentes, Atara, Caribou, Sangamo And Pliant Announce Changes

New appointments announced over the past week include new CEOs at C4 Therapeutics and ORIC pharma, COO at CytRx, President at Audentes, global R&D head at Atara, CBO at Caribou, CTO at Sangamo, and chairman at Pliant.

 

Appointments Leadership

Global CRISPR Revolution Gathers Pace, Raising Hopes – And Concerns

CRISPR technology was invented just five years ago but is so accurate, versatile, easy to use, and inexpensive that it has spread quickly through biology laboratories, giving researchers new tools to interrogate biology and make precise alterations to an organism’s genetic material, offering its potential use in a wide array of therapies.

Scrip 100 Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Caribou Biosciences Inc.
  • Senior Management
  • Rachel Haurwitz, PhD, CEO & President
    Steve Canner, PhD, CSO
    Scott Gradia, PhD, VP, Platform Research
    Chris Fuller, PhD, VP, Informatics
    Timothy F Herpin, PhD, CBO
  • Contact Info
  • Caribou Biosciences Inc.
    Phone: (510) 982-6030
    2929 7th St.
    Ste. 105
    Berkeley, CA 94710
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register